生物制剂治疗巨细胞动脉炎的研究进展

Research progress in the treatment of giant cell arteritis with biological agents

巨细胞动脉炎(GCA)是一种原因不明、以侵犯大动脉为主的坏死性血管炎,好发于50岁以上人群,是严重威胁老年人群健康水平的疾病之一。长期以来,GCA的治疗以糖皮质激素为基石,需大剂量、长疗程诱导和维持缓解,药物不良反应明显,减量后易复发,是临床亟待解决的主要问题。生物制剂为自身免疫性疾病的治疗开辟了新领域。随着对GCA发病机制认识的不断深入,生物制剂治疗GCA的临床研究取得了具有一定价值的支持性证据。文章综合阐述多种生物制剂治疗GCA的相关临床研究,为其临床应用提供理论依据。

Giant cell arteritis(GCA)is a kind of necrotizing vasculitis with unknown cause,which mainly invades the great arteries.It is prone to occur in people over 50 years old.It is one of the diseases that seriously threaten the health level of the elderly.For a long time,the treatment of GCA is based on glucocorticoid,which needs large dose,long course of induction and maintenance of remission,obvious adverse drug reactions,easy to relapse after reduction,which is the main problem to be solved in clinic.Biological agents have opened up a new field for the treatment of autoimmune diseases.With the further understanding of the pathogenesis of GCA,the clinical study of biological agents in the treatment of GCA has obtained some valuable supporting evidence.In this paper,the related clinical studies of GCA treatment with various biological agents were reviewed,which provided theoretical basis for its clinical application.